^
Association details:
Biomarker:SBK1 overexpression
Cancer:Melanoma
Drug Class:PD-L1 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma

Published date:
08/15/2022
Excerpt:
Further analysis showed that in lung cancer responders, CD69 was upregulated while SBK1 was downregulated and that in melanoma responders, both were upregulated….CD69 and SBK1 are potential predictors of response to cancer immunotherapy using PD-1/PD-L1 blockade.
DOI:
10.3389/fimmu.2022.952059